Highmark Interactive Announces Collaboration with Mayo Clinic to Assess Impact of “Long COVID” on Cognitive Function
Highmark Interactive Inc. Begins trading on the TSX Venture Exchange

TORONTO, Oct. 05, 2021 (GLOBE NEWSWIRE) — BrainFx, a wholly owned subsidiary of Highmark Interactive, today announces its collaboration with Mayo Clinic to assess the impact of “Long COVID” or “Post-COVID-19 Syndrome” on cognitive function. Long COVID, according to recent studies, affects somewhere between 10 and 40 percent of people who have had COVID-19, even in those with mild or no symptoms. The most common symptoms of Long COVID include shortness of breath, cognitive dysfunction (or ‘brain fog’) and fatigue and can negatively impact a person’s ability to complete their daily activities, including work or school.

Much is still unknown about how COVID-19 will affect people over time which is why it is critical to develop a better understanding of who it impacts, how it impacts them and for how long. By assessing which functional cognitive skills are being affected when COVID-19 brain-related symptoms are reported and tracking this in the context of a person’s history, Mayo Clinic and Highmark will employ the BrainFx platform to assist researchers in tracing the symptoms to objective areas of physiologic dysfunction or other contributing factors. This improved understanding can assist with treatment decisions, and support health providers with clinically useful, data-driven insights that can help with rehabilitation in people with Long COVID.

The teams will leverage the medical expertise of Mayo Clinic Drs. Vanichkachorn and Cowl and Highmark’s BrainFx Virtual Cognitive Assessment platform to develop and pilot the COVID-19 Cognitive Recovery Tracker™ (CCRT) first within Mayo Clinic sites and then expand the pilot nationally.

“Our collaboration with Mayo Clinic to better understand and track the effects of Long COVID is critical and urgent work. The insights we will gain from our collaboration have the potential to improve the quality of life for the many people coping with Long COVID. We were excited when we added the BrainFx organization and technology to the Highmark group of companies and are now proud to work with such esteemed and knowledgeable collaborators at Mayo Clinic,” says Dr. Sanjeev Sharma, CEO of Highmark.

For more information:

About Highmark
Highmark Interactive was created to change the paradigm of testing and management for brain and mental health. Highmark’s approach is focused on providing real-time data to health providers to support proactive, preventative interventions and targeted care planning to improve health outcomes.

Highmark Interactive acquired BrainFx in May 2021 to complement its FDA cleared, EQ patient-led assessments of neurofunction with BrainFx’s clinician-led assessments of neurofunction. Together, the technology is used in >300 multidisciplinary rehabilitation clinics globally.

Highmark Interactive’s unique solution is revolutionizing how individuals experience brain and mental health care, as well as unlocking insight for precision medicine and creating a modern model for delivering mental health and neurorehabilitation services. Learn more: https://www.highmark.tech/

Media Contacts:
Highmark Interactive: Don Harkness, don@highmark.tech

Interested in working with us?

Get in touch with us below to learn more

Let's make the INVISIBLE effects of brain disorders VISIBLE, together.

BrainFx logo

Copyright © 2022 - BrainFx. All rights reserved.

Important Information: BrainFx Assessments only provide information about neurofunctional performance. Assessment results detail the patient/client's performance on assessment activities completed and only assist the health care team in identifying potential areas of strength or challenge as related to function. Assessments DO NOT provide any diagnosis or treatment recommendations. BrainFx Assessments are only permitted to be delivered by trained clinicians. Assessment reports are not stand-alone and require the interpretation of a health professional within their scope of practice and in the context of all information that they have gathered about their patient/client. In Canada, BrainFx Assessments are cleared by Health Canada as a Class 1 Software as a Medical Device. BrainFx Assessments and the statements made on this website have not been evaluated by any other regulatory bodies. Assessments are not intended to diagnose, treat, cure, or prevent any disease. Information provided by BrainFx is not a substitute for face-to-face consultation with your health care professional and should not be construed as individual medical advice.